A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy, with an Open-Label Extension Save

Date Added
March 26th, 2019
PRO Number
Pro00085211
Researcher
Ekrem Kutluay

List of Studies


Profiles_link
Keywords
Epilepsy
Summary

This study is to evaluate how safe the study drug XEN1101 is for patients with focal epilepsy when it is taken with the patients standard epileptic medications.

This investigational drug has been tested in healthy volunteers but this is the first time it will be tested in participants with focal-onset epilepsy. The study consists of 3 phases;a screening /baseline phase lasting 4 weeks to confirm participants qualify to enroll in the study, a treatment phase in which participants may or may not receive study drug lasting 8 weeks with 6 study visit appointment visits, and an optional extension phase in which participants will receive study drug for a year with 6 study visits appointments.

Institution
MUSC
Recruitment Contact
Robin Bulgarino
843-792-1115
Bulgarino@musc.edu

Change_preferences

-- OR --

Create_login